GENEA BIOMEDX GEMS
LIVE

Serial Number

79171360

Owner

Genea IP Holdings Pty Ltd

Attorney

Eric Lamb

Filing Date

Jun 12, 2015

Add to watchlist:

No watchlists yet
View on USPTO

GENEA BIOMEDX GEMS Trademark

Serial Number: 79171360 • Registration: 5029077

GENEA BIOMEDX GEMS is a trademark filed by Genea IP Holdings Pty Ltd on June 12, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Genea IP Holdings Pty Ltd (15 trademarks)

L2,

Entity Type: 98

Trademark Details

Filing Date

June 12, 2015

Registration Date

August 30, 2016

Published for Opposition

June 14, 2016

Goods & Services

Cell culture media other than for medical or veterinary use, namely, for laboratory use in relation to researching, diagnosing and/or treating infertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivation; cell culture media other than for medical or veterinary use, namely, for scientific and research use in relation to researching, diagnosing and/or treating infertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivation; human cell products, namely, pluripotent and differentiated human cells and stem cells for research or scientific purposes; human cell products, namely, pluripotent and differentiated human cells and stem cells for laboratory use excluding medical and veterinary use; biological and chemical products and substances for scientific use other than for medical or veterinary use, namely, chemicals for use in science in relation to researching, diagnosing and/or treating infertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivation, chemical preparations for scientific purposes in relation to researching, diagnosing and/or treating infertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivation, biological preparations to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes, chemical preparations to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes, chemical reagents for scientific use in relation to researching, diagnosing and/or treating fertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivation

Culture media for medical use for use to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes for medical purposes; cell culture media for medical use for use to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes for medical purposes; human cell products, namely, pluripotent and differentiated human cells and stem cells for medical or clinical use; cell culture media for use in medical or medical research applications for cultivating human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes; biological and chemical products and substances for medical use excluding dietary supplements, nutritional supplements, vaccines and antibiotics, namely, chemicals for medical or clinical use in relation to assisted reproductive therapies, cell fertilisation, cell division and cell cultivation and diagnosing and/or treating fertility and other disorders relating to fertility and reproduction, chemical preparations for medical or clinical use in relation to assisted reproductive therapies, cell fertilisation, cell division and cell cultivation and diagnosing and/or treating fertility and other disorders relating to fertility and human reproduction, chemical preparations for the treatment of infertility and other disorders relating to fertility and human reproduction, biological preparations for the treatment of infertility and other disorders relating to fertility and human reproduction, biological preparations to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes, chemical preparations to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes, chemical reagents for medical use in relation to assisted reproductive therapies, cell fertilisation, cell division and cell cultivation and diagnosing and/or treating fertility and other disorders relating to fertility and reproduction; pharmaceutical preparations for the treatment of infertility and other disorders relating to fertility and human reproduction, excluding dietary supplements, nutritional supplements, vaccines and antibiotics

Filing History

TEAS SECTION 71 RECEIVED
Sep 16, 2026 ES71
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Aug 30, 2025 REM4
INTERNATIONAL REGISTRATION RENEWED
Jul 3, 2025 RNWL
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Sep 8, 2023 NA71
REGISTERED-SEC.71 ACCEPTED
Sep 8, 2023 71AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 7, 2023 APRE
TEAS SECTION 71 RECEIVED
Feb 20, 2023 ES71
NEW REPRESENTATIVE AT IB RECEIVED
Jan 7, 2022 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Aug 30, 2021 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Feb 15, 2019 NREP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 18, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 18, 2019 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 17, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 1, 2017 FICS
FINAL DISPOSITION PROCESSED
Feb 1, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 30, 2016 FICR
REGISTERED-PRINCIPAL REGISTER
Aug 30, 2016 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 22, 2016 OPNX
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 13, 2016 TCCA
PUBLISHED FOR OPPOSITION
Jun 14, 2016 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 1, 2016 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 1, 2016 OP2R
NOTICE OF PUBLICATION
May 25, 2016 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
May 7, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 7, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 7, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 7, 2016 TROA
REFUSAL PROCESSED BY IB
Oct 24, 2015 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 8, 2015 RFCS
REFUSAL PROCESSED BY MPU
Oct 8, 2015 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 7, 2015 RFCR
NON-FINAL ACTION WRITTEN
Oct 6, 2015 CNRT
ASSIGNED TO EXAMINER
Sep 22, 2015 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 8, 2015 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 2, 2015 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 27, 2015 REPR